The University of Navarra and business 3P Biopharmaceuticals have signed a agreement to promote training and research in technology and production of new drugs, especially biotechnological ones. This agreement of partnership aims to reinforce the figure of the pharmacist and other health science professionals as expert scientists, to collaborate with the academic world in the development of the knowledge industrial and drug manufacturing, as well as to promote their training.

The agreement also aims to maximize the use of new technologies and drive the digital transformation of the pharmaceutical industry. The partnership between the University of Navarra and 3P Biopharmaceuticals, a leader in the development of processes and manufacturing of biopharmaceutical and cell therapy products, has a clear goal of financial aid to society and will have a group of interdisciplinary experts, with complementary specializations and expertise. 

The areas of interest of this agreement address new medicine and advanced therapies at research and development, among others, the development of drugs from subject biologics and cell and gene therapy, manufacturing and analytical technology, dispensing technology, with the goal final goal of manufacturing increasingly safer drugs, with increasingly fewer side effects, or oriented to diseases that, until now, have no cure or with treatments with serious side effects.

Strengthening Navarre's strategic commitment to health
For the Vice President of research of the University of Navarra, Iciar Astiasarán, "the COVID-19 and the development of several types of vaccines in record time have shown the importance of a solid health system and of the research and innovation in the world of medicine. We are confident that the agreement we signed with 3P Biopharmaceuticals will serve to strengthen Navarra's strategic commitment to health for the benefit of all citizens".

From agreement with the CEO of 3P Biopharmaceuticals, Dámaso Molero, "through this agreement 3P sample its support to the creation of technical-scientific talent that contributes knowledge to a growing and dynamic sector such as biotechnology. I hope that as a result of this partnership we will continue to add value to Navarra and the Spanish biopharmaceutical sector".

The University of Navarra and 3P Biopharmaceuticals also want to promote the programs of study of Degree and Master's Degree biopharmaceuticals for which prizes and scholarships will be created. The pharmaceutical signature and the academic center will organize activities, courses, seminars and scientific meetings. The agreement has been signed for a period of five years. The business 3P Biopharmaceuticals is committed to finance the necessary equipment and materials and to make its facilities available to the academic center. The University, for its part, will be responsible for disseminating and publishing the results and advances derived from this agreement of partnership.